App-Quantinova.ai

Utility of susceptibility weighted imaging in the objective diagnosis of idiopathic Parkinson’s Disease: Is DaTscan necessary?

R. Ellis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Validation of actigraphy-derived sleep metrics in Parkinson’s disease (PD) patients and elderly controls, taking into account clinical and physiological status

J. Munro - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Validation of Computerised Measures of Executive Functioning for use in Parkinson’s Disease Assessments.

T. Dominey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Weight loss in Parkinson’s disease (PD)

K. Khalid - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

What impacts relationship satisfaction in Parkinsonian dementias?

S. Vatter - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lewy body dementia

N/A

‘PDSAFE’ – A multi-dimensional fall rehabilitation intervention for people with Parkinson’s with specialist physiotherapy training: qualitative exploration of physio’s experiences

K. Seymour - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A detailed clinical study of pain in 1957 participants with Parkinson’s disease

M. Silverdale - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A framework to facilitate competence in practice for Parkinson’s Disease Nurse Specialists in the United Kingdom

H. Martin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A longitudinal PET study to assess progression of laterality in Parkinson’s disease

AA. Roussakis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A new distinct spastic ataxia with hypomyelination: Clinical, neuroimaging and molecular expression of NKX6-2 mutations

V. Chelban - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Spastic ataxia

N/A

A panel of CSF and plasma biomarkers reveals novel biological insights into atypical parkinsonian syndromes

E. Jabbari - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

A post-mortem and in vivo study of neuroinflammation and Toll like-receptors in Parkinson’s disease

A. Kouli - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Candesartan cilexetil

Accessing Speech and Language Therapy (SLT) in a Multi-Disciplinary Movement Disorders Clinic (MDC)

J. Martin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Acid sphingomyelinase deficiency rescues mitochondrial dysfunction in gba-/- zebrafish (Danio rerio)

M. Keatinge - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Niemann-Pick disease type A

N/A

Adult neurogenesis is impaired in pink1-/- zebrafish (Danio rerio)

S. Bandmann - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

L-Tyrosine

An evaluation of the availability and format of information provided to patients who have a new diagnosis of Parkinson’s disease (PD)

L. Ebenezer - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

An international survey of stiff person spectrum disorders: Exploring the clinical spectrum and unmet needs

B. Balint - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Apathy in rapid eye movement sleep behaviour disorder is associated with serotonin depletion in the raphe nuclei

T. Barber - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Depression

Ioflupane

Assessing working memory dysfunction with letter n-back functional MRI task in early-stage Parkinson’s disease

A. Martin-Bastida - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Attitudes to Palliative Care in Movement Disorder Physicians in the UK

L. Wiblin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts